Skip to content
Live
Trending storyPast story

MMDesign technical report

1 reports1 outlets21 days agoUpdate

The story so far

AI overview

MMDesign has made breakthrough progress in the field of AI pharmaceuticals. The MMDesign AI protein de novo design platform has completed 18 design projects with a success rate of 94.7%, hitting all six GPCR targets, with the best affinity reaching nanomolar level. The platform uses a 'generate-screening-verification' workflow, generating tens of thousands of candidate molecules in the computational space and testing only 9-50 to achieve success, with an overall candidate hit rate of 30.7%. Each project only tests 9-50 candidate molecules, 18 projects obtaining experimentally confirmed binding molecules with a project success rate of 94.7%; all six tested GPCR targets were successful, with the best affinities at the nanomolar level; for six previously hit targets, design was redone, with five projects showing further improvement in the design results.

AI-written from the reports · Updated 21 days ago

Coverage timeline

Follow the coverage to see every side of the story.

28 Oct
  1. QbitAI
    MolCell MMDesign achieves breakthrough progress in the AI pharmaceutical field

    MolCell AI's MMDesign platform completes 18 design projects with a success rate of 94.7%, hitting all six GPCR targets among them, with the best affinity reaching nanomolar level; the platform uses a 'generate-screen-verify' workflow, generating tens of thousands of candidate molecules in computational space and testing only 9-50 to achieve success, with an overall candidate hit rate of 30.7%, demonstrating efficient and precise molecular design capabilities.